Quantitative analysis of sponsorship bias in economic studies of antidepressants

Background Concern is widespread about potential sponsorship influence on research, especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such studies is limited. Aims To determine whether there is an association between sponsorship and quantitative outcomes in pharmacoeconomic studies of antidepressants. Method Using all identifiable articles with original comparative quantitative cost or cost-effectiveness outcomes for antidepressants, we performed contingency table analyses of study sponsorship and design v. study outcome. Results Studies sponsored by selective serotonin reuptake inhibitor (SSRI) manufacturers favoured SSRIs over tricyclic antidepressants more than non-industry-sponsored studies. Studies sponsored by manufacturers of newer antidepressants favoured these drugs more than did non-industry-sponsored studies. Among industry-sponsored studies, modelling studies favoured the sponsor's drug more than did administrative studies. Industry-sponsored modelling studies were more favourable to industry than were non-industry-sponsored ones. Conclusions Pharmacoeconomic studies of antidepressants reveal clear associations of study sponsorship with quantitative outcome.

[1]  The Role of Clinical “Experience” in Diagnostic Performance , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  D. Sclar,et al.  Antihypertensive pharmacotherapy: Economic outcomes in a health maintenance organization , 1994 .

[3]  M. Hotopf,et al.  Are SSRIs a Cost-Effective Alternative to Tricyclics? , 1996, British Journal of Psychiatry.

[4]  Gagnon Jp.  Sources of bias in the economic analysis of new drugs. Health Outcomes Committee Pharmaceutical Research and Manufacturers of America, Washington, DC. , 2000 .

[5]  G A Colditz,et al.  Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.

[6]  J. Rosenbaum,et al.  Health economics of depression , 1993 .

[7]  B. Mcfarland.  Cost-effectiveness considerations for managed care systems: treating depression in primary care. , 1994, The American journal of medicine.

[8]  W. Crown,et al.  Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. , 1998, Journal of affective disorders.

[9]  E. Berndt,et al.  Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety. , 2002, Managed care interface.

[10]  S. Montgomery,et al.  Economic Analysis of Treating Depression with Nefazodone v. Imipramine , 1996, British Journal of Psychiatry.

[11]  T. Lair,et al.  Effect of antidepressant therapy on health care utilization and costs in primary care. , 1997, Psychiatric services.

[12]  J. Sacristán,et al.  Publication bias in health economic studies. , 1997, PharmacoEconomics.

[13]  D. Sclar,et al.  Economic appraisal of citalopram in the management of single-episode depression. , 1999, Journal of clinical psychopharmacology.

[14]  S. Woods,et al.  Cost-effectiveness of antidepressant treatment reassessed , 1997, British Journal of Psychiatry.

[15]  S. Hill,et al.  Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. , 2000, JAMA.

[16]  J. Russell,et al.  Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. , 1999, The American journal of managed care.

[17]  R. Davidson.  Source of funding and outcome of clinical trials , 1986, Journal of general internal medicine.

[18]  C. Bell,et al.  The Quality of Reporting in Published Cost-Utility Analyses, 19761997 , 2000, Annals of Internal Medicine.

[19]  T. Einarson,et al.  Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. , 1997, PharmacoEconomics.

[20]  J. Forder,et al.  A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. , 1996, Journal of affective disorders.

[21]  C. Bell,et al.  Are pharmaceuticals cost-effective? A review of the evidence. , 2000, Health affairs.

[22]  D. Sclar,et al.  Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. , 1998, The Journal of clinical psychiatry.

[23]  D. Rennie,et al.  Pharmacoeconomic analyses: making them transparent, making them credible. , 2000, JAMA.

[24]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[25]  S. Arikian,et al.  A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  B. Hillman,et al.  Frequency and Costs of Diagnostic Imaging in Office Practice‐A Comparison of Self‐Referring and Radiologist‐Referring Physicians , 1990, The New England journal of medicine.

[27]  M. Friedberg,et al.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology. , 1999, JAMA.

[28]  B. Luce.  Policy Implications of Modeling the Cost-Effectiveness of Health Care Technologies , 1995 .

[29]  P. Rochon,et al.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. , 1994, Archives of internal medicine.

[30]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[31]  S. Arikian,et al.  THE HEALTH ECONOMIC IMPACT OF ANTIDEPRESSANT USAGE FROM A PAYER'S PERSPECTIVE: A MULTINATIONAL STUDY , 2001, International journal of clinical practice.

[32]  B Kinosian,et al.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. , 1991, The New England journal of medicine.

[33]  F. Meurgey,et al.  The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. , 1994, Journal of affective disorders.

[34]  A. Stewart.  Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs , 1994 .

[35]  Henry T. Stelfox,et al.  Conflict of interest in the debate over calcium-channel antagonists. , 1998, The New England journal of medicine.

[36]  T A Sheldon,et al.  Problems of using modelling in the economic evaluation of health care. , 1996, Health economics.

[37]  J. Guest,et al.  Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria , 1999, European Psychiatry.

[38]  S. Woods,et al.  Cost-effectiveness of newer antidepressants , 1997 .

[39]  T. Kniesner,et al.  Effect of Antidepressant Choice on the Incidence and Economic Intensity of Hospitalization Among Depressed Individuals , 2000, Administration and Policy in Mental Health and Mental Health Services Research.

[40]  G. Oster,et al.  Predictors of a medical-offset effect among patients receiving antidepressant therapy. , 1998, The American journal of psychiatry.

[41]  T. Einarson,et al.  A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. , 1995, Clinical therapeutics.

[42]  J. Borghi,et al.  Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK , 2000, European Psychiatry.

[43]  B. O'brien,et al.  Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? , 1996, Medical care.

[44]  M Mandelkern.  Manufacturer support and outcome. , 1999, The Journal of clinical psychiatry.

[45]  P. Bebbington,et al.  What Price Depression? , 1994, British Journal of Psychiatry.

[46]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[47]  Y. Lapierre,et al.  Direct Cost of Depression: Analysis of Treatment Costs of Paroxetine versus Imipramine in Canada , 1995, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[48]  P. Neumann,et al.  Paying the Piper for Pharmacoeconomic Studies , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[49]  N A Azimi,et al.  The effectiveness of cost-effectiveness analysis in containing costs , 1998, Journal of general internal medicine.

[50]  D. Sclar,et al.  Antidepressant Pharmacotherapy: Economic Evaluation of Fluoxetine, Paroxetine and Sertraline in a Health Maintenance Organization , 1995, The Journal of international medical research.

[51]  D. Rennie,et al.  Publication bias. The triumph of hope over experience. , 1992 .

[52]  Z. Khan,et al.  Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[53]  A. Detsky.  Using cost-effectiveness analysis for formulary decision making: from theory into practice. , 1994, PharmacoEconomics.

[54]  Ruth E. Brown,et al.  Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. , 1997, The Journal of clinical psychiatry.

[55]  J. Bitran,et al.  Cost-effectiveness analysis: sleeping with an enemy or a friend? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  W. Katon,et al.  Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. , 1999, Archives of family medicine.

[57]  D Menon,et al.  Canadian Coordinating Office for Health Technology Assessment. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[58]  D. Sclar,et al.  Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression , 1995 .

[59]  Anton Sf,et al.  The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. , 1995 .

[60]  Alan Cantor,et al.  The uncertainty principle and industry-sponsored research , 2000, The Lancet.